GlassScriptPhysician profile
Rita Thanga
NPI 1508480229
$8,939.14
in general payments reported to CMS, 2019-2025
17 companies · $2,004 in 2025
The $2,004 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $1,918 · 2023: $2,195 · 2024: $2,029 · 2025: $2,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,081 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,080.78 |
| Education | $146.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,210.83 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $2,031.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,297.93 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,024.96 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $540.92 | 2023-2025 | Auvelity |
| Alkermes, INC. | $440.96 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $289.27 | 2023-2025 | Ingrezza |
| Tris Pharma INC | $274.55 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Teva Pharmaceuticals USA, INC. | $221.63 | 2022-2023 | Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $196.12 | 2024-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $130.14 | 2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $114.75 | 2023 | Quviviq |
| Indivior INC. | $75.98 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.76 | 2024 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.11 | 2025 | Abilify Maintena |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $22.95 | 2025 | Adzenys Xr-Odt |
| Janssen Biotech, INC. | $11.80 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Thanga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.